Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...
Veru (NASDAQ:VERU – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 6th. Analysts expect Veru to post earnings of ($0.08) per share and ...
MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Competitive Intelligence in Breast Cancer: Tracking the Evolving HR+ HER2-ve Breast Cancer Landscape
A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...
Veruschka Foundation trains people with developmental disabilities in culinary and essential life skills that will help them ...
CARLSBAD, Calif. - ImpediMed, known for its medical technology in fluid and body composition monitoring, has secured a five-year $15 million growth capital facility with SWK Holdings Corporation ...
After hours: 7:26:54 p.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback